Accenture Chief Executive Officer (CEO) Julie Sweet has disclosed a health update in an internal mail to employees. The CEO has been diagnosed with early-stage breast cancer, with treatment expected ...

Plus: All the news and watercooler chat from Fortune. Good morning. Accenture CEO Julie Sweet announced yesterday that her breast cancer has come back, noting in a memo to staff that “the ...

Julie Spellman Sweet, Chair and CEO of Accenture plc (NYSE:ACN), recently sold a significant portion of her holdings in the company. According to a regulatory filing, Sweet disposed of 7,793 Class ...

Accenture CEO Julie Sweet was praised this week for her openness regarding a breast cancer diagnosis, which also gave rare insight into how executives disclose their life-altering health news.

Today, Accenture plc (NYSE:ACN), a $243 billion market cap technology consulting giant, disclosed an update on the health of Julie Sweet, the company's Chair and Chief Executive Officer.

Good morning. Accenture CEO Julie Sweet announced yesterday that her breast cancer has come back, noting in a memo to staff that “the prognosis from my doctor is excellent; the cancer was caught ...

Accenture CEO Julie Sweet has been diagnosed with early-stage breast cancer and the treatment is likely to last 12-16 weeks, according to a Moneycontrol report. However, the CEO will continue to look ...